Literature DB >> 15184382

Necessity of oligonucleotide aggregation for toll-like receptor 9 activation.

Christina C N Wu1, Jongdae Lee, Eyal Raz, Maripat Corr, Dennis A Carson.   

Abstract

Toll-like receptor 9 (TLR9), a member of the interleukin-1 (IL-1) family of pathogen-associated molecular pattern receptors, is activated by unmethylated CpG-containing sequences in bacterial DNA or synthetic oligonucleotides (ODNs) in the endosomal compartment. The stimulation of an IL-1 response is thought to require the aggregation of its receptor. By analogy, we postulated that the potency of a TLR9 ligand should depend first on its ability to enter cells and gain access to TLR9 and second on its capacity to form a multimeric complex capable of cross-linking these receptors. Previously, we selected from a random library a series of phosphodiester ODNs with enhanced ability to permeate cells. Here, we studied the structural requirements for these penetrating ODNs to elicit a functional TLR9 response, as assessed by cytokine production from bone marrow-derived mouse mononuclear cells. The presence of a prototypic murine immunostimulatory DNA hexameric sequence (purine-purine-CG-pyrimidine-pyrimidine) in the ODNs was not sufficient for stimulation. In addition, the TLR9-activating ODNs had to have the ability to form aggregates and often to form secondary structures near the core CpG motifs. Multimerization was promoted by the presence of a guanine-rich 3'-terminus. The phosphodiester ODNs with CpG motifs that did not aggregate antagonized the effects of the multimeric TLR9 activators. These findings suggest that an optimal TLR9 agonist needs to contain a spatially distinct multimerization domain and a receptor binding CpG domain. This concept may prove useful for the design of new TLR9-modulating agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184382     DOI: 10.1074/jbc.M311662200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.

Authors:  Klaus Zwiorek; Carole Bourquin; Julia Battiany; Gerhard Winter; Stefan Endres; Gunther Hartmann; Conrad Coester
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

2.  Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation.

Authors:  Makiya Nishikawa; Mitsuhiro Matono; Sakulrat Rattanakiat; Nao Matsuoka; Yoshinobu Takakura
Journal:  Immunology       Date:  2008-01-23       Impact factor: 7.397

Review 3.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

4.  Attenuated activation of macrophage TLR9 by DNA from virulent mycobacteria.

Authors:  Alexandra K Kiemer; Ryan H Senaratne; Jessica Hoppstädter; Britta Diesel; Lee W Riley; Koichi Tabeta; Stefan Bauer; Bruce Beutler; Bruce L Zuraw
Journal:  J Innate Immun       Date:  2008-07-02       Impact factor: 7.349

5.  Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.

Authors:  Robert F Ashman; J Adam Goeken; Petar S Lenert
Journal:  Int Immunopharmacol       Date:  2011-03-02       Impact factor: 4.932

6.  Dual Toll-Like Receptor Targeting Liposomal Spherical Nucleic Acids.

Authors:  Jennifer R Ferrer; Jason A Wertheim; Chad A Mirkin
Journal:  Bioconjug Chem       Date:  2019-03-04       Impact factor: 4.774

7.  Structure-dependent modulation of alpha interferon production by porcine circovirus 2 oligodeoxyribonucleotide and CpG DNAs in porcine peripheral blood mononuclear cells.

Authors:  Frida Hasslung Wikström; Brian M Meehan; Mikael Berg; Sirje Timmusk; Josefine Elving; Lisbeth Fuxler; Mattias Magnusson; Gordon M Allan; Francis McNeilly; Caroline Fossum
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

8.  Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.

Authors:  Nicholas M Molino; Amanda K L Anderson; Edward L Nelson; Szu-Wen Wang
Journal:  ACS Nano       Date:  2013-10-09       Impact factor: 15.881

9.  In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model.

Authors:  Christina C N Wu; Mojgan Sabet; Tomoko Hayashi; Rommel Tawatao; Joshua Fierer; Dennis A Carson; Donald G Guiney; Maripat Corr
Journal:  Cell Immunol       Date:  2008-05-20       Impact factor: 4.868

10.  Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand.

Authors:  Christina C N Wu; Tomoko Hayashi; Kenji Takabayashi; Mojgan Sabet; Donald F Smee; Donald D Guiney; Howard B Cottam; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.